Annovis Bio (ANVS) said Tuesday that the US Food and Drug Administration has approved its revised protocol for a pivotal phase 3 trial of buntanetap as potential treatment for Alzheimer's disease.
Instead of conducting two separate trials, the new protocol combines a six-month symptomatic study and an 18-month disease-modifying study into one integrated 6/18-month trial, which begins this month, the company said.
Shares of the company were down 4.7% in recent trading.
Price: 5.10, Change: -0.25, Percent Change: -4.67
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments